Key Points

  • Approximately 30% of psoriasis patients will develop psoriatic arthritis (PsA), often after several years.
  • Psoriasis is among the most prevalent autoimmune diseases in the USA; approximately 2.2% of the population have psoriasis.
  • PsA may be characterized by inflammatory peripheral arthritis, skin and nail involvement, enthesitis, dactylitis, axial arthritis, and other manifestations.
  • PsA can be remarkably diverse among patients in its presentation and course.
  • Significant recent developments in understanding of the immunopathology of disease have helped drive the availability of major therapeutic advances. Along with progress in disease assessment, these required an update of the 2009 GRAPPA treatment recommendations.
  • These recommendations are specifically relevant only for patients with PsA and not intended for juvenile idiopathic arthritis or psoriasis without arthritis.
  • These recommendations are evidence based to the greatest extent possible, and were developed by an international, multidisciplinary group with substantial patient input.